PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.27%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
264.51%
Other expenses change of 264.51% while RVPH maintains costs. Bruce Berkowitz would investigate efficiency.
3.15%
Operating expenses growth while RVPH reduces costs. John Neff would investigate differences.
3.15%
Total costs growth while RVPH reduces costs. John Neff would investigate differences.
-0.34%
Both companies reducing interest expense. Martin Whitman would check industry trends.
-75.00%
D&A reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine efficiency.
15.50%
EBITDA growth exceeding 1.5x RVPH's 5.85%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
16.24%
Operating income growth exceeding 1.5x RVPH's 7.11%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-3.90%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.90%
Tax expense growth less than half of RVPH's 52.58%. David Dodd would verify if advantage is sustainable.
12.65%
Net income growth exceeding 1.5x RVPH's 5.90%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
12.55%
EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
12.55%
Diluted EPS growth exceeding 1.5x RVPH's 7.69%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.